EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is a validated target in non-small-cell lung cancer (NSCLC).
• Osimertinib, a third-generation EGFR inhibitor, faces resistance due to the EGFR C797S mutation, an unmet clinical need.
• Fourth-generation EGFR inhibitors are under development but lack clinical efficacy data.

Purpose of the Study:

• To review structural properties of EGFR, resistance mechanisms, and mutations.
• To focus on recent advances in EGFR-targeting degraders, including PROTACs.
• To discuss the advantages and challenges of EGFR degraders in NSCLC.

Main Methods:

• Literature review of EGFR inhibitors and resistance mechanisms.
• Analysis of novel EGFR-targeting degraders, such as Proteolysis-Targeting Chimeric Molecules (PROTACs).
• Comparison of cellular potency, inhibition, and toxicity profiles of degraders versus inhibitors.

Main Results:

• EGFR mutations, particularly C797S, confer resistance to existing therapies like osimertinib.
• EGFR-targeting degraders, derived from EGFR-TKIs and natural products, demonstrate enhanced cellular potency and improved toxicity profiles.
• PROTACs represent a promising strategy to overcome EGFR-mediated drug resistance.

Conclusions:

• EGFR-targeting degraders offer a potential solution to overcome C797S-mediated resistance in NSCLC.
• Further research and clinical validation are needed for EGFR degraders.
• Targeted protein degradation is an emerging therapeutic modality for drug-resistant cancers.